Exothera

Executive Summary

Exothera is a Belgian contract development and manufacturing organization (CDMO) specializing in viral vector production for gene and cell therapies and vaccines. Founded in 2019 and headquartered in Gosselies, the company offers process development, GMP manufacturing, and analytical services for lentivirus and AAV vectors, supporting clients from pre-clinical through commercial stages. As the demand for advanced therapies rises, Exothera is positioned to capture a share of the growing CDMO market, which is driven by increasing gene therapy approvals and pipeline expansion. The company's focus on high-quality, scalable production could enable it to win contracts from both biotech startups and large pharmaceutical companies seeking reliable viral vector supply. However, Exothera operates in a competitive landscape with established players, and its relatively recent founding means it must continue to demonstrate operational excellence and capacity reliability. The company's ability to secure long-term partnerships and expand its manufacturing footprint will be key to its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new manufacturing capacity expansion (e.g., additional GMP suites or a second facility)60% success
• TBDStrategic partnership or multi-year supply agreement with a leading gene therapy developer50% success
• Q4 2026Launch of a new viral vector platform or enhanced analytical service offering70% success